5-bromo-1-(2-carboxyethyl)-3-(1-imidazolylmethyl)indole | 76894-83-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-bromo-1-(2-carboxyethyl)-3-(1-imidazolylmethyl)indole
• 英文别名: 3-(5-Bromo-3-imidazol-1-ylmethyl-indol-1-yl)-propionic acid；3-[5-bromo-3-(imidazol-1-ylmethyl)indol-1-yl]propanoic acid
• CAS: 76894-83-2
• 化学式: C₁₅H₁₄BrN₃O₂
• 分子量: 348.199
• InChiKey: VGAGUWZSTXVJNP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  60
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  甲基磺酰胺 、 5-bromo-1-(2-carboxyethyl)-3-(1-imidazolylmethyl)indole 在 N,N'-羰基二咪唑 作用下， 以 甲醇 、 乙醇 、 氯仿 为溶剂， 生成 5-bromo-1-[2-(N-methanesulphonylcarbamoyl)ethyl]-3-(1-imidazolylmethyl)indole
  参考文献：
  名称：

  Inhibition of thromboxane synthetase by 3-(1-Imidazolylalkyl) indoles

  摘要：

  本文披露了新型3-(1-咪唑基烷基)吲哚化合物及其药用酸盐。这些新型化合物可用于选择性抑制血栓素合酶酶的作用，而不显著抑制前列环素合酶或环氧合酶的作用，因此对于治疗缺血性心脏病、中风、短暂性缺血性发作、血栓形成、偏头痛和糖尿病的血管并发症具有治疗价值。

  公开号：

  US04273782A1
• 作为产物：
  描述：

  3-[5-bromo-3-(imidazol-1-ylmethyl)indol-1-yl]propanenitrile 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 4.0h， 以61%的产率得到5-bromo-1-(2-carboxyethyl)-3-(1-imidazolylmethyl)indole
  参考文献：
  名称：

  Selective thromboxane synthetase inhibitors. 2. 3-(1H-Imidazol-1-ylmethyl)-2-methyl-1H-indole-1-propanoic acid and analogs.

  摘要：

  The preparation of a series of 3-(1H-imidazol-1-ylmethyl)-1H-indole-1-alkanoic acids is described. Several compounds were found to be more potent thromboxane synthetase inhibitors than the corresponding analogues lacking an acidic substituent. In the cases examined, compounds had no significant activity against PGI2 synthetase or cyclooxygenase, and introduction of the carboxylic acid substituent led to a reduction in activity against adrenal steroid 11 beta-hydroxylase. Compound 21 strongly inhibited thromboxane formation after iv administration to anesthetized rabbits and oral administration to conscious dogs. The compound had a long duration of action, and marked inhibition of thromboxane production was observed 15 h after oral administration of 1 mg/kg to conscious dogs.

  DOI：

  10.1021/jm00153a007

文献信息

• CROSS, P. E.;DICKINSON, R. P.;PARRY, M. J.;RANDALL, M. J., J. MED. CHEM., 1986, 29, N 3, 342-346
  作者：CROSS, P. E.、DICKINSON, R. P.、PARRY, M. J.、RANDALL, M. J.

  DOI：——

  日期：——
• CATALYTIC INK ADJUSTMENT METHOD
  申请人：NISSAN MOTOR CO., LTD.

  公开号：EP2763221B1

  公开（公告）日：2016-12-07
• JPS5665802A
  申请人：——

  公开号：JPS5665802A

  公开（公告）日：1981-06-03
• CATALYTIC INK PREPARATION METHOD
  申请人：Toyoshima Kenichi

  公开号：US20140228200A1

  公开（公告）日：2014-08-14

  A catalytic ink preparation method comprises mixing a first ion conducting body and a catalyst, preparing a first ink, and concentrating the first ink. The method is characterized by further comprising a step of adding a second ion conducting body to the concentrated first ink. With such a catalytic ink preparation method, the quantity of solvent in the first ion conducting body is reduced by concentration. In other words, the first ion conducting body adheres to the catalyst, and re-dissolution is not prone to occurring with the first ion conducting body when the second ion conducting body is added. Thus, it is possible to efficiently manufacture an electrode catalyst in which a significant part of the surface of the catalyst is covered with two ionomer layers, and there is almost no portion which is covered with only one ionomer layer.
• US4273782A
  申请人：——

  公开号：US4273782A

  公开（公告）日：1981-06-16